The short answer. A LIQITOMIC franchise is not a retail business. It is a territory licence to deploy a UK-developed alkaline hydrolysis system that treats anatomical and organic waste on-site — inside hospitals, laboratories, veterinary clinics and biomedical facilities — as an alternative to sending that waste off-site for incineration. The right partner is an operator with institutional healthcare relationships and a compliance mindset, not a food-service background. If that describes you, LIQITOMIC is one of the more defensible service concepts currently available to develop across Asia Pacific and MENA.
LIQITOMIC is an anatomical waste treatment technology developed by Sanondaf, the UK decontamination specialist operating since 2014. Rather than collecting, freezing, packaging and transporting anatomical waste to a centralised incinerator, LIQITOMIC treats it where it is generated, using a controlled alkaline hydrolysis process that breaks down tissue, bone and skin and neutralises the result for standard discharge.
The process runs in three stages — preparation, treatment under controlled conditions, and a result designed to substantially reduce waste mass. Treatment typically completes in under an hour. The units are compact and portable enough to be installed at the point where waste is produced, which removes the handling and transport steps that make conventional disposal both expensive and risky.
The technology was developed through an 18-month project and validated in scientific trials at a leading UK university, then proven in commercial operation. According to the brand, reductions in waste mass vary with material type and operating conditions — a useful piece of honesty, and one worth repeating to any prospective client who expects a single universal number.
Most cross-border franchise opportunities ask an investor to import consumer demand. This one asks something easier: to serve demand that already exists and is regulated into existence.
Every hospital, teaching university, veterinary group and research laboratory in every market VF operates in produces anatomical waste, and every one of them is subject to health, safety and environmental rules governing its disposal. Sustainability reporting has tightened the screw further, because incineration is an emissions line item that increasingly has to be explained. LIQITOMIC lets an institution treat waste at source, in line with the environmental and health-safety expectations set out in UN and WHO guidance, without building a relationship with a distant processing facility.
That produces a business with three characteristics institutional investors like: contracted, recurring revenue from clients who cannot simply stop generating waste; long sales cycles that become long retention, because once a unit is installed and staff are trained, switching is disruptive; and no exposure to consumer fashion, which is what eventually catches out most single-concept F&B investors.
LIQITOMIC is the healthcare-facing expression of the same engineering group behind Sanondaf’s B2B decontamination model. Investors who already understand that category will recognise the buyer, the procurement cycle and the compliance vocabulary immediately. For those coming from a different sector, it belongs to the broader shift we mapped in our review of non-food service franchise opportunities across Asia Pacific and MENA, where recurring B2B contracts have been quietly outperforming footfall-dependent formats.
| Market cluster | Primary demand driver | Operator profile that fits |
|---|---|---|
| GCC (Saudi Arabia, UAE, Qatar, Kuwait) | Rapid hospital and medical-city build-out, plus national sustainability agendas that make emissions reduction a procurement criterion | Medical equipment distributors and healthcare services groups with existing ministry and private-hospital relationships |
| Southeast Asia (Singapore, Malaysia, Thailand, Vietnam, Indonesia, Philippines) | Fast-expanding private hospital groups and a growing veterinary and life-sciences base, often ahead of centralised disposal infrastructure | Hospital supply and facilities-management companies capable of national coverage and local regulatory navigation |
| India | Very large institutional base across hospitals, universities and research facilities, with strong pressure on logistics costs | Established healthcare infrastructure players with regional service teams and after-sales capability |
| North Asia (Japan, Korea, Taiwan) | Mature regulatory frameworks, high environmental expectations and strong institutional willingness to adopt validated technology | Technical distributors with a track record of certifying and supporting imported medical systems |
| Australia and New Zealand | Concentrated hospital and veterinary networks with detailed environmental reporting obligations | Facilities-services groups already contracted into healthcare estates |
This is a technical, institutional sale. The partner profile is unusually specific, which is a good sign: brands that will license to anyone tend to be brands with nothing worth protecting.
VF publishes a single figure for this brand: an investment level of US$250,000, which should be read as the entry commitment for a territory rather than a full business plan. Everything beyond that — territory scope, term, and the structure of the agreement — is set case by case with the brand, which is why the directory lists those rows as available on request.
Practically, the resources that matter are less about the cheque and more about the platform: a technical service team, a regulatory pathway, warehousing and logistics for units and consumables, and enough working capital to carry long institutional sales cycles before the recurring revenue base matures. Partners who already run a healthcare distribution business are effectively adding a line to an existing platform rather than building one.
The sequence that works is the same one we apply to every cross-border advisory mandate: confirm the regulatory route before the commercial one. In some markets anatomical waste treatment is governed by environmental authorities, in others by health ministries, and in several by both. Establishing which approvals a LIQITOMIC deployment requires — and how long they take — is the first piece of work, not the last.
From there, the market-entry mechanics are country-specific. Registration and structuring differ considerably between Vietnam, Singapore, India, Saudi Arabia and the UAE, and getting the structure wrong is considerably more expensive than getting it right slowly. Technical details of the system itself are set out on the official LIQITOMIC website.
Generally, no — and that is a feature rather than a limitation. The buyer is an institution, the sale is technical, and credibility comes from existing relationships. Investors drawn to the sector but without a healthcare platform are usually better served by a service model with a shorter sales cycle, such as the concepts covered in our review of clinic-based service brands.
Conventional clinical waste management collects and transports waste to a centralised facility, usually for incineration. LIQITOMIC treats anatomical and organic waste at the point of generation using alkaline hydrolysis, removing the collection, freezing, packaging and transport steps entirely.
Hospitals and medical centres, veterinary clinics and animal research facilities, universities and biomedical laboratories, and emergency or field operations where portable treatment capability has obvious value.
Territory availability is not published. VF manages availability directly with the brand, and serious enquiries are matched against current commitments before any discussion of rights begins.
Expect regulatory groundwork and the first institutional installation to dominate the first twelve to eighteen months, with the compounding effect of reference clients arriving afterwards. This is a patient-capital model, and partners who treat it as one tend to end up owning the category in their market.
If your business already sits inside the healthcare estate in an Asia Pacific or MENA market, LIQITOMIC is worth a conversation before someone else has it.
Email: info@vffranchiseconsulting.com | Hotline: +84 90 306 54 58
Author: Sean T. Ngo, CEO and Co-founder of VF Franchise Consulting.
